Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid Regression: Immunohistochemistry, Histopathology and Imaging Study

The clinical trial will be carried out at the Gatot Soebroto Army Central Hospital, Jakarta and planned from June 2020 to December 2020. Clinical trials of Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs) and Conditioned Medium Umbilical Cord-Mesenchymal Stem Cells (CM UC-MSCs) for Keloid were designed in three groups. Group 1 injected with The UC-MSCs at a dose of 2 million cells / cm3 using a 1 cc injection syringe (27G) by intra-lesion injection and booster with CM UC-MSCs at a dose of 1 cc / cm3 using a 1 cc injection syringe (27G) by intra-lesion injection and booster with CM UC-MSCs at the same dose 3 weeks later. Group 3 injected with Triamcinolon acetonide (TA) at a dose of 40 mg / cc / cm3 using 1 cc (27 G) syringe and booster with TA at 3 weeks later. The study subjects each group amounted to 7 patients suffering from Keloid. Patients were evaluated for 3 months after injection.

开始日期2020-09-01

申办/合作机构

PT Prodia Stemcell Indonesia

NCT04260698

/ Completed临床3期

An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.

开始日期2020-07-08

申办/合作机构

Gamida Cell Ltd.

NCT03173937

/ Recruiting临床1/2期IIT

Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, to Expedite Engraftment and Improve Transplant Outcome

Background:
Severe aplastic anemia (SAA) and myelodysplastic syndrome (MDS) are bone marrow diseases. People with these diseases usually need a bone marrow transplant. Researchers are testing ways to make stem cell transplant safer and more effective.
Objective:
To test if treating people with SAA or MDS with a co-infusion of blood stem cells from a family member and cord blood stem cells from an unrelated donor is safe and effective.
Eligibility:
Recipients ages 4-60 with SAA or MDS
Donors ages 4-75
Design:
Recipients will be screened with:
* Blood, lung, and heart tests
* Bone marrow biopsy
* CT scan
Recipients will have an IV line placed into a vein in the neck. Starting 11 days before the transplant they will have several chemotherapy infusions and 1 30-minute radiation dose.
Recipients will get the donor cells through the IV line. They will stay in the hospital 3-4 weeks. After discharge, they will have visits:
* First 3-4 months: 1-2 times weekly
* Then every 6 months for 5 years
Donors will be screened with:
* Physical exam
* Medical history
* Blood tests
Donors veins will be checked for suitability for stem cell collection. They may need an IV line to be placed in a thigh vein.
Donors will get Filgrastim or biosimilar (G-CSF) injections daily for 5-7 days. On the last day, they will have apheresis: Blood drawn from one arm or leg runs through a machine and into the other arm or leg. This may be repeated 2 days or 2-4 weeks later.

开始日期2017-06-13

申办/合作机构

National Heart, Lung & Blood Institute

100 项与 Omidubicel (Gamida Cell) 相关的临床结果

登录后查看更多信息

100 项与 Omidubicel (Gamida Cell) 相关的转化医学

登录后查看更多信息

100 项与 Omidubicel (Gamida Cell) 相关的专利（医药）

登录后查看更多信息

项与 Omidubicel (Gamida Cell) 相关的文献（医药）

2026-01-01·Stem Cell Reviews and Reports

Opening New Horizons: Advanced Hematopoietic Stem Cell Expansion Strategies Bridging Cord Blood Therapy from Bench To Bedside

Review

作者: Zhao, Yunyan ; Zhang, Yu ; Du, Wei ; Liu, Rongzhi ; Li, Guangzhao

Hematopoietic stem cell transplantation has been conducted in clinical settings to treat patients with malignant or non-malignant blood diseases for decades. Cord blood (CB) has been recognized as an essential graft source with beneficial characteristics, such as a lower risk of relapse and a lower rate of chronic graft-versus-host disease. However, the limited number of cells in CB impedes its broader use and hinders the ability to harness its benefits. Various expansion strategies have emerged to address this barrier, based on a deeper understanding of fate decisions and the maintenance of stemness in hematopoietic stem cells. To achieve an efficient transition from the laboratory to clinical application, several strategies have successfully managed scale-up manufacturing to satisfy clinically relevant requirements for both quality and scale. These approaches have progressed to the clinical stage and have demonstrated promising results. Novel expanded CB-derived hematopoietic stem and progenitor cells (HSPCs) therapies, including OMISIRGE (Omidubicel onlv.), Zemcelpro (Dorocubicel), and upcoming products with International Nonproprietary Name designations, introduce innovative concepts and comprehensive considerations for improving CB transplantation. This progress enables novel therapeutic options and represents a breakthrough in traditional CB transplants. In this context, we summarize and explore representative techniques and products to provide insights that inspire future developments in CB-derived HSPC therapies.

2025-08-01·Blood neoplasia

Outcomes of myeloablative allogeneic hematopoietic cell transplantation with omidubicel vs alternative donor sources

Article

作者: He, Chujun ; Burns, Linda J ; Xu, Chunyi ; Tang, Xiao-Ying ; Sajeev, Gautam ; Zhang, Mei-Jie ; Horwitz, Mitchell E ; Simantov, Ronit ; Sivaraman, Smitha ; Signorovitch, James E ; Song, Yan ; Shin, Heayoung ; Lin, Chenyu

Omidubicel is a nicotinamide-expanded stem cell product derived from umbilical cord blood (UCB). In a phase 3 randomized trial for high-risk hematologic malignancies, omidubicel had faster neutrophil engraftment and fewer infectious complications than standard UCB transplantation. However, the clinical outcomes of omidubicel relative to other stem cell donor sources are yet to be determined. Clinical data for patients who underwent allogeneic hematopoietic cell transplantation (HCT) with omidubicel and standard UCB were taken from the phase 3 trial. The Center for International Blood and Marrow Transplant Research (CIBMTR) registry provided contemporaneous comparator cohorts of patients who met the trial eligibility criteria and who received allogeneic HCT from matched unrelated (MUD), mismatched unrelated (7/8 MMUD), and haploidentical donors. A total of 951 patients met the eligibility criteria, including 52 for omidubicel, 56 for standard UCB, 65 for 7/8 MMUD, 450 for MUD, and 328 for haploidentical donors. Omidubicel was associated with more rapid neutrophil engraftment than all other donor sources but slower platelet engraftment relative to other donor sources aside from UCB. There were no significant differences in overall survival, disease-free survival, and nonrelapse mortality among the donor sources. Omidubicel had a higher incidence of grade 2 to 4 acute graft-versus-host disease (GVHD), but similar rates of grade 3 to 4 acute GVHD and chronic GVHD compared to the CIBMTR cohorts. These results support the role of omidubicel as a viable donor source in the current transplant landscape.

2025-07-01·Transplantation and Cellular Therapy

Omidubicel-onlv Transplantation for Hematologic Malignancies: Results of a Multicenter Expanded Access Program

Article

作者: Rezvani, Andrew R ; Schiller, Gary J ; Tsai, Stephanie B ; Levy, Stuart ; Mazor, Roei D ; Maziarz, Richard T ; Goshen, Uri ; Schwarzbach, Aurélie ; Stiff, Patrick J ; Horwitz, Mitchell E

Omidubicel-onlv is an FDA-approved, nicotinamide-modified, allogeneic hematopoietic progenitor cell therapy derived from umbilical cord blood (UCB). A phase 3 study demonstrated improved hematopoietic recovery and decreased infections with omidubicel compared with UCB allogeneic transplantation. We report results of an Expanded Access Program evaluating clinical outcomes in patients with hematologic malignancies following transplantation with omidubicel. Between August 2020 and May 2023, 29 patients were transplanted at 5 US sites. Patients received myeloablative conditioning, prophylactic and therapeutic medications, and supportive care per institutional guidelines, and were monitored for engraftment, infections, and graft-versus-host-disease (GVHD) for up to 2 years post-transplant. Results were compared with previously reported phase 3 outcomes. Omidubicel recipients had a median age of 39 (range 20-73, 62% male); 45% were non-White and 65.5% had acute leukemia. Median follow-up was 11.8 (range: .3-27.7) months. Median neutrophil and platelet engraftment times were 12 and 33.5 days, respectively. Acute GVHD (grade 3-4) at day 100 occurred in 19% of patients, with chronic GVHD at 1 year in 9% of patients, all of which were mild. First grade 2 to 3 bacterial infections through 100 days post-transplant and first grade 3 viral infection 1 year post-transplant occurred in 18% and 12% of patients, respectively. One-year disease-free survival and overall survival rates were 76% and 87%, respectively. This real-world study of omidubicel transplantation for hematologic malignancies finds that this graft source is commonly used for non-White allogeneic transplant recipients. The rapid engraftment kinetics observed following transplantation with omidubicel appears to have addressed excessive nonrelapse mortality that has been previously observed following myeloablative umbilical cord blood transplantation.

138

项与 Omidubicel (Gamida Cell) 相关的新闻（医药）

2026-02-09

·BioSpace

Ayrmid Appoints ACA Pharma as Exclusive Distributor for Omisirge(R) across Greater China and Southeast Asia

ACA Pharma granted exclusive rights to register and distribute Omisirge across 15 markets, covering both FDA-approved Omisirge indications DUBLIN, IE / ACCESS Newswire / February 9, 2026 / Ayrmid, Ltd. ("Ayrmid" or the "Company"), the parent company of Gamida Cell Inc., today announced that it has appointed ACA Pharma as its exclusive distributor for Omisirge (Omidubicel-onlv) and granted ACA Pharma exclusive rights to seek registration and to distribute Omisirge across the following jurisdictions: Mainland China, Hong Kong SAR, Macau SAR, Mongolia, Brunei Darussalam, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, Philippines, Singapore, Thailand, Vietnam and Timor-Leste. Under the terms of the agreement, ACA Pharma will hold exclusive rights to register and distribute Omisirge across the Territory; the parties will prioritize specific jurisdictions for regulatory and launch planning based on local requirements and commercial considerations. Initial efforts may focus on lighthouse centers in Macau and Singapore, with additional jurisdictions assessed over time. Dr. Joe Wiley, CEO and Chairman of Ayrmidcommented: "This agreement represents continued progress as we expand access for patients in existing and new territories. Omisirge represents an important advancement in cell therapy and we look forward to working with the team at ACA as we continue to advance our innovative therapies to help patients with serious unmet medical needs." Mike Zhou, CEO of ACA Pharmacommented: "This appointment reflects a shared commitment to responsibly expanding access to Omisirge for appropriate patients across Greater China and Southeast Asia. ACA Pharma's platform is built for complex specialty products-combining regulatory execution, hospital launch capability, and end-to-end distribution-while maintaining the highest standards for quality and patient safety." About Omisirge Omisirge is a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood. Omisirge is approved in the United States for: (1) adults and pediatric patients 12 years and older with hematologic malignancies planned for umbilical cord blood transplantation following myeloablative conditioning to reduce time to neutrophil recovery and incidence of infection; and (2) adults and pediatric patients 6 years of age and older with severe aplastic anemia following reduced-intensity conditioning. About Ayrmid Ltd. and Gamida Cell Ayrmid Ltd. is the parent company of Gamida Cell Inc., a pioneering cell therapy company developing novel treatments designed to turn cells into powerful therapeutics. Gamida Cell Inc. currently has two FDA approved products on the market in the US, namely Omisirge ® (please see the current full Prescribing Information, including boxed warning, here ) and APHEXDA ® (please see the current full Prescribing Information here ). Gamida Cell operates as a wholly owned subsidiary of Ayrmid Limited, a UK entity. For additional information, please visit or follow Gamida Cell on LinkedIn , X , Facebook or Instagram . Contacts: Media, Investors / Business Development: bd@ayrmid.com About ACA Pharma Founded in 1997, ACA Pharma is a U.S.-headquartered company specializing in fast-track registrations, early access programs, and end-to-end commercialization for innovative medicines and medical devices worldwide. The company is best known for its Macau Fast-Track platform for medicines and Hong Kong Fast-Track pathway for advanced devices, which can enable market entry in as little as 30-90 days in Macau and approximately three months in Hong Kong. These hubs then serve as launchpads to bridge into mainland China via the Greater Bay Area and other national pilot zones, with the real-world evidence generated supporting accelerated national approvals - particularly for products addressing unmet medical need, clinically urgent conditions, or rare diseases. Learn more at This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit . SOURCE: Ayrmid Pharma Ltd View the original press release on ACCESS Newswire

细胞疗法引进/卖出上市批准临床研究加速审批

2026-02-05

·BioSpace

Ayrmid and Ariti Sign Distribution Agreement for Omisirge(R) in Greece and Cyprus

DUBLIN, IE / ACCESS Newswire / February 5, 2026 / Ayrmid, Ltd. ("Ayrmid" or the "Company"), the parent company of Gamida Cell Inc., today announced that it has entered into an exclusive distribution agreement with Ariti S.A., a Greece based pharmaceutical company for the distribution of Omisirge (Omidubicel-onlv) in Greece and Cyprus. Under the terms of the agreement, Ariti will provide services to support early access schemes to Omisirge in the agreed territories, leveraging its established expertise in hematology and local market infrastructure. Dr. Joe Wiley, Chief Executive Officer and Chairman of Ayrmidccommented: "This agreement represents continued progress as we expand access for patients in existing and new territories. We look forward to working with the team at Ariti and we remain deeply committed to advancing innovative therapies to help patients with serious unmet medical needs." Mr. Serafeim Kyrkos, Chief Executive Officer of Ariti S.A.commented: "This collaboration brings together our broad expertise in hematology with Ayrmid's innovative therapies, including Omisirge, the only FDA approved cell therapy for allogenic transplant for hematologic malignancies and for the treatment of Severe Aplastic Anemia. For both companies, this represents a tremendous opportunity to support market access in Greece and Cyprus, while driving mutual growth in the haemato-oncology segment". About Omisirge Omisirge is a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood. Omisirge is approved in the United States for: (1) adults and pediatric patients 12 years and older with hematologic malignancies planned for umbilical cord blood transplantation following myeloablative conditioning to reduce time to neutrophil recovery and incidence of infection; and (2) adults and pediatric patients 6 years of age and older with severe aplastic anemia following reduced-intensity conditioning. About Ayrmid Ltd. and Gamida Cell Ayrmid Ltd. is the parent company of Gamida Cell Inc., a pioneering cell therapy company developing novel treatments designed to turn cells into powerful therapeutics. Gamida Cell Inc. currently has two FDA approved products on the market in the US, namely Omisirge ® (please see the current full Prescribing Information, including boxed warning, here ) and APHEXDA ® (please see the current full Prescribing Information here ). Gamida Cell operates as a wholly owned subsidiary of Ayrmid Limited, a UK entity. For additional information, please visit or follow Gamida Cell on LinkedIn , X , Facebook or Instagram . Contacts: Media, Investors / Business Development: bd@ayrmid.com About Ariti S.A. Ariti S.A., founded in 1985, is a well-established Greek healthcare company active in the pharmaceutical and medical sector. Over the past decades, the Company has built a strong track record in the exclusive representation, distribution and commercialization of pharmaceutical and healthcare products in Greece, in collaboration with reputable international partners. With extensive local expertise, Ariti leverages a solid commercial and regulatory infrastructure to support market access and broad product availability across Greece and Cyprus. Ariti also maintains an owned nationwide network of 10 chronic hemodialysis care units in Greece, strengthening its healthcare footprint and supporting its long-term commitment to improving patient outcomes. For additional information, please visit Ariti SA or follow Ariti SA on LinkedIn This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit . SOURCE: Ayrmid Pharma Ltd View the original press release on ACCESS Newswire

引进/卖出细胞疗法上市批准免疫疗法生物类似药

2026-02-05

·BioSpace

Ayrmid Pharma Ltd Announces Additional Positive Results for Omisirge(R) in Treating Severe Aplastic Anemia (SAA) Presented at TANDEM

Omisirge transplantation shows accelerated immune recovery in SAA New data presented at the 2026 TANDEM Meetings demonstrate that patients with SAA who received Omisirge experienced faster and more robust immune recovery compared with patients receiving alternative transplant graft sources Omisirge approved by FDA as First Cell Therapy to Treat Severe Aplastic Anemia Key Highlights of Data Presented at TANDEM: Rapid neutrophil recovery: Median time to neutrophil engraftment was 10 days following Omisirge transplantation. Faster recovery was associated with higher transplanted CD34⁺ cell doses Enhanced CD4⁺T-cell reconstitution: At six months post-transplant, CD4⁺ T-cell counts were significantly higher in Omisirge recipients compared with other transplant sources including matched and haploidentical donors. Higher CD4⁺ T-cell recovery correlated with more rapid neutrophil engraftment Accelerated NK-cell recovery: Natural killer (NK) cell reconstitution occurred early after transplant, with median NK-cell counts at days 30 and 100 exceeding those observed across all comparator graft sources Omisirge approved by the FDA on December 5, 2025 for SAA DUBLIN, IE / ACCESS Newswire / February 5, 2026 / Ayrmid Ltd. ("Ayrmid" or the "Company"), the parent company of Gamida Cell Inc., a leader in cell therapy innovation, today announced further positive interim clinical results for Omisirge (Omidubicel-onlv), its advanced stem cell transplant therapy for Severe Aplastic Anemia (SAA). The data showed that patients with SAA who received Omisirge transplants experienced faster and more robust immune recovery compared with patients receiving other transplant graft sources, including HLA-matched donor peripheral blood stem cells, haploidentical donors with post-transplant cyclophosphamide, standard cord blood, and combined cord/haploidentical transplants. The findings come from an ongoing single-center Phase II study conducted at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) and were presented by investigators from NHLBI/NIH and collaborating institutions at the 2026 Transplantation & Cellular Therapy meetings of ASTCT ® and CIBMTR ® (TANDEM), taking place from February 4-7, 2026 in Salt Lake City, UT. Alternative donor hematopoietic cell transplantation (HCT) has historically been limited in SAA by delayed engraftment and high rates of graft rejection. Omisirge is a nicotinamide-expanded cord blood product designed to increase the number of hematopoietic stem and progenitor cells available for transplantation. Dr. Richard Childs of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH) commented: "In this study, we observed that Omisirge transplantation was associated with faster neutrophil engraftment and earlier recovery of key immune cell populations compared with historical transplant approaches in SAA. These findings suggest that enhanced stem cell dose may translate into improved early immune reconstitution in this high-risk patient population." Dr. Ronit Simantov, Chief Medical and Scientific Officer of Ayrmid commented: "These results highlight the significant potential of Omisirge as a transplant option for patients with SAA. The enhanced immune recovery observed following Omisirge transplantation may have important clinical implications for patients with SAA, including improved engraftment, reduced risk of graft rejection, and potentially lower susceptibility to infections in the post-transplant period. We remain deeply committed to advancing transformative therapies for patients with serious unmet medical needs." Omisirge is now approved for treatment in adults and pediatric patients 6 years of age and older with SAA following reduced intensity conditioning. The FDA approval of Omisirge was based on data from the 17-H-0091 study. About Severe Aplastic Anemia Severe Aplastic Anemia is a rare, life-threatening hematologic disorder in which the bone marrow fails to produce sufficient blood cells. Stem cell transplantation offers a potential cure; however, many patients lack a matched sibling donor. Ayrmid is advancing therapies to address this unmet medical need. About Ayrmid Ltd. and Gamida Cell Ayrmid Ltd. is the parent company of Gamida Cell Inc., a pioneering cell therapy company developing novel treatments designed to turn cells into powerful therapeutics. Gamida Cell Inc. currently has two FDA approved products on the market in the US, namely Omisirge ® (please see the current full Prescribing Information, including boxed warning, here ) and APHEXDA ® (please see the current full Prescribing Information here ). Gamida Cell operates as a wholly owned subsidiary of Ayrmid Limited, a UK entity. For additional information, please visit or follow Gamida Cell on LinkedIn , X , Facebook or Instagram . Contacts: Media, Investors / Business Development: bd@ayrmid.com This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit . SOURCE: Ayrmid Pharma Ltd View the original press release on ACCESS Newswire

临床结果细胞疗法免疫疗法临床2期上市批准

100 项与 Omidubicel (Gamida Cell) 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
再生障碍性贫血	美国	Gamida Cell Ltd.	2025-12-08
血液肿瘤	美国	Gamida Cell Ltd.	2023-04-17

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性白血病	临床3期	美国	Gamida Cell Ltd.	2016-12-16
急性白血病	临床3期	巴西	Gamida Cell Ltd.	2016-12-16
急性白血病	临床3期	法国	Gamida Cell Ltd.	2016-12-16
急性白血病	临床3期	以色列	Gamida Cell Ltd.	2016-12-16
急性白血病	临床3期	意大利	Gamida Cell Ltd.	2016-12-16
急性白血病	临床3期	荷兰	Gamida Cell Ltd.	2016-12-16
急性白血病	临床3期	葡萄牙	Gamida Cell Ltd.	2016-12-16
急性白血病	临床3期	新加坡	Gamida Cell Ltd.	2016-12-16
急性白血病	临床3期	西班牙	Gamida Cell Ltd.	2016-12-16
急性白血病	临床3期	英国	Gamida Cell Ltd.	2016-12-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Tandem Meetings ASTCT and CIBMTR2026	N/A	移植物抗宿主病	18	Omidubicel	選範鑰壓餘顧範鹽鏇鹽(膚夢膚膚觸獵網鹹鏇襯) = 築廠鏇顧蓋夢憲憲簾餘襯壓窪窪鹹糧遞壓糧鹽 (窪範鑰構廠鏇獵觸衊膚 ) 更多	积极	2026-02-04
				Omidubicel	顧製積襯遞製鬱廠艱觸(鏇醖鏇窪觸願餘鹹範鏇) = 鬱選鏇齋糧糧襯觸膚製醖築艱鏇鏇艱廠顧憲遞 (鏇範築繭網選遞餘獵糧 ) 更多
BusinessWire 人工标引	临床1期	再生障碍性贫血	14	Omidubicel	糧鏇糧構鹽積願觸鬱鹹(獵選齋餘糧簾餘壓築鹹) = 憲顧鑰蓋衊餘簾顧膚繭壓觸鏇積觸積範鹽積簾 (遞壓蓋鏇襯積觸範蓋鹽 ) 更多	积极	2025-10-28
NCT02730299 (Tandem Meetings ASTCT and CIBMTR2024) 人工标引	临床3期	血液肿瘤	-	Omidubicel (EAP)	糧獵淵壓鏇衊遞衊餘醖(鑰艱蓋淵獵鹹衊選醖衊) = 憲膚膚襯蓋鏇襯願憲鑰糧醖製製顧構齋齋鏇齋 (鹹遞淵艱夢構範淵艱築 ) 更多	积极	2024-02-22
				omidubicel (P3-OMI)	糧獵淵壓鏇衊遞衊餘醖(鑰艱蓋淵獵鹹衊選醖衊) = 壓願襯願網糧鹹製夢憲糧醖製製顧構齋齋鏇齋 (鹹遞淵艱夢構範淵艱築 ) 更多
NCT02730299 (Pubmed \| Transplant Cell Ther)	临床3期	血液肿瘤	108	Omidubicel-onlv	觸蓋鏇鬱獵夢齋壓窪範(繭憲獵壓簾壓鏇鏇鹹廠) = 構積觸蓋餘餘鹽鑰繭壓衊蓋築構廠淵衊鹹鑰襯 (製餘繭淵壓夢繭蓋鬱觸 ) 更多	积极	2023-12-01
				Umbilical Cord Blood Transplantation	觸蓋鏇鬱獵夢齋壓窪範(繭憲獵壓簾壓鏇鏇鹹廠) = 餘積壓願窪簾簾積範廠衊蓋築構廠淵衊鹹鑰襯 (製餘繭淵壓夢繭蓋鬱觸 ) 更多
NCT02730299 (Phase 3 Substudy, Pubmed \| Transplant Cell Ther)	临床3期	器官移植排斥	37	Omidubicel	鏇鑰鏇鹹壓簾構廠餘廠(襯衊艱艱願鏇齋顧衊簾) = 鏇製鬱齋遞膚積築築壓顧獵獵蓋憲遞廠膚繭築 (鹹糧鹹鬱範襯蓋鏇鹹網 ) 更多	积极	2023-08-01
				Omidubicel (Standard UCB)	膚築襯顧顧夢餘窪襯淵(範蓋鏇夢膚鑰齋簾糧鑰) = 簾積廠齋鏇憲簾願構築顧網淵積鑰衊選鏇鹽齋 (糧鬱餘遞衊觸鹹遞醖壓 )
NCT02730299 (FDA) 人工标引	临床3期	血液肿瘤	125	OMISIRGE	鏇願範顧鏇窪齋鹽餘顧(積廠醖鹹糧繭壓蓋膚夢) = 窪醖憲鑰積簾襯窪襯構積齋築膚壓夢選膚鏇餘 (膚簾構獵糧簾網觸選壓, 10 ~ 15) 更多	优效	2023-04-17
				Umbilical Cord Blood	鏇願範顧鏇窪齋鹽餘顧(積廠醖鹹糧繭壓蓋膚夢) = 廠觸選膚構鏇憲願憲遞積齋築膚壓夢選膚鏇餘 (膚簾構獵糧簾網觸選壓, 19 ~ 25) 更多
phase III trial (SOHO2022)	临床3期	造血干细胞移植	108	Omidubicel	築壓顧築衊構鑰糧艱築(構齋積襯簾鹹鏇窪顧選) = 襯廠範選選願醖鹽夢鹽構鹽遞艱繭窪蓋齋醖觸 (範淵淵憲繭齋構範願餘, p = 0.04) 更多	积极	2022-10-01
SOHO2022	临床3期	造血干细胞移植	116	Omidubicel	鑰鹹選淵簾艱築夢鹽獵(構窪鑰艱壓夢築糧鑰鏇) = 夢淵艱觸蓋製淵製簾範網蓋膚範願網遞襯網糧 (鹹壓醖鑰淵糧遞襯範廠, 47.0–67.1) 更多	积极	2022-10-01
Phase III Randomized, Multicenter Study (Tandem Meetings ASTCT and CIBMTR2022)	临床3期	-	125	Omidubicel	鹹鏇膚願艱構積選齋網(製蓋夢窪餘鬱醖鬱夢壓) = 範餘選憲範廠構繭齋鏇糧鹽壓網襯顧願願製網 (簾廠鑰簾鏇壓窪網築鹹, -10% ~ 23%) 更多	积极	2022-03-01
				Omidubicel (Standard Myeloablative Umbilical Cord Blood Transplantation (UCBT))	鹹鏇膚願艱構積選齋網(製蓋夢窪餘鬱醖鬱夢壓) = 齋餘餘鑰鏇鏇獵衊鬱鏇糧鹽壓網襯顧願願製網 (簾廠鑰簾鏇壓窪網築鹹 ) 更多
NCT02730299 (phase III, Tandem Meetings ASTCT and CIBMTR2022)	临床3期	血液肿瘤	-	Omidubicel	襯壓廠範觸積衊簾糧觸(鬱簾鏇獵齋鬱壓廠餘鹽) = 淵築遞鏇壓網齋簾鬱膚鹹獵築範鬱遞選襯衊醖 (餘範願觸艱鑰糧廠積範 ) 更多	积极	2022-03-01
				Omidubicel (Umbilical Cord Blood (UCB))	襯壓廠範觸積衊簾糧觸(鬱簾鏇獵齋鬱壓廠餘鹽) = 選遞鏇構鏇艱醖繭願製鹹獵築範鬱遞選襯衊醖 (餘範願觸艱鑰糧廠積範 ) 更多